New weight-loss drug Retatrutide showing stronger results than current options
Sunday, May 24 – A new weight-loss drug, so new it is not on the market yet, is showing promising results in trials, doing much more than what current medications can. Dr. Jon LaPook breaks it down.
GLP-1s Linked to Lower Risk of Cancer Spread in Four Tumor Types
Sunday, May 24 – (MedPage Today) — CHICAGO — Use of GLP-1 receptor agonists in patients with four solid tumor types was significantly associated with lower rates of progression to metastatic disease over a 5-year period, a propensity score-matched analysis…
GLP-1 drugs may reduce the risk of cancer progressing, study suggests
Sunday, May 24 – GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week at the American Society of Clinical Oncology’s annual meeting.
As GLP-1 drugs surge in popularity, bariatric surgery rates plunge across the US
Sunday, May 24 – For a very long time, bariatric surgery, in which doctors removed a portion of the stomach, was the standard procedure for helping patients lose weight and manage obesity, alongside metabolic disorders such as diabetes, high blood pressure, and high cholesterol. However, ever since GLP-1 medications like Ozempic became available on the market, there has been a shift in how people seek to lose weight.
Stoking Sexual Arousal and Desire: GLP-1s, Nerve Stimulation, ‘Scream Cream’
Sunday, May 24 – (MedPage Today) — WASHINGTON — Interest in GLP-1 receptor agonists as a potential aid to sexual desire and arousal disorders took off in the field of sexual medicine — and landed with a thud.
“GLP-1s are not what I would call treatments…
New Weight Loss Drug Retatrutide Delivers Stunning Results
Sunday, May 24 – Remarkable new test results by drugmaker Eli Lilly reveal that their latest weight loss drug, retatrutide, may be even more effective than the three popular GLP-1s currently available. The new drug is designed to mimic three hormones responsible for hunger regulation and fat burning. NBC’s medical contributor Dr. Natalie Azar breaks down the trial results and discusses how soon the new drug is likely to get FDA approval.
Popular GLP-1 weight-loss drugs like Ozempic slash heart attack and stroke risk
Sunday, May 24 – A huge international review found that GLP-1 weight-loss drugs significantly reduce the risk of heart attacks, strokes, heart failure, and premature death over the long term. Researchers say these medications could become a major weapon against cardiovascular disease — not just obesity and diabetes.
‘Wild West’ peptide craze surges beyond GLP-1s as FDA faces pressure to ease access
Thursday, May 21 – The peptide market is surging alongside GLP-1 demand, creating tension between compounding pharmacies and commercial drug companies over patient access.
Eli Lilly Loses Bid To Limit Ex-FDA Chief’s Take In GLP-1 MDL
Thursday, May 21 – A Pennsylvania federal judge said Eli Lilly & Co. and plaintiffs in multidistrict litigation accusing it of downplaying side effects of weight loss drugs were talking past each other in a dispute over expert testimony, denying Eli Lilly’s bid to limit the opinions of the plaintiffs’ expert to those disclosed in his report.
Driven by GLP-1s, pharma’s relationship with consumers is starting to change
Thursday, May 21 – Pharmaceutical companies’ ability to interact with the patients taking their medications has changed over the last few years.
The rise of direct-to-consumer channels, driven largely by consumer willingness to pay for GLP-1s for weight loss …